Maternal AI chatbot shows zero postpartum mental health gain

Access to Rosie, an AI chatbot for maternal health, showed no statistically significant anxiety or depression benefit at 12 months compared with a monthly children's book program in a 400-person randomized trial.

The study, published Nov. 4 in JAMA Network Open, tested access to health advice among pregnant and postpartum participants with generally low starting symptom scores.

Rosie was designed to answer maternal and infant health questions, offer personalized guidance, and provide reminders and educational support. A clinical social worker reviewed distress alerts, contacted participants, and provided resources, so the intervention included human support alongside the chatbot.

Researchers assigned 200 participants to each group. The US study enrolled English-speaking people aged 14 or older who were pregnant or parenting an infant younger than six months and identified as members of racial or ethnic minoritized groups.

Enrollment ran from October 2023 through December 2024, with follow-up completed in December 2025.

The primary measures were self-reported anxiety symptoms on the GAD-7 questionnaire and depression symptoms on the PHQ-9 questionnaire. The 12-month analyses included 361 participants for anxiety and 362 for depression.

The adjusted difference between the chatbot and control groups was 0.10 points for anxiety, with a 95% confidence interval of -0.77 to 0.96. For depression, it was -0.23 points, with an interval of -1.05 to 0.59.

Both intervals include zero, leaving uncertainty about the size and direction of any underlying effect. The trial established neither a clear benefit nor equivalence between the approaches.

Read the two primary outcomes

Anxiety: adjusted mean difference 0.10 points. The 95% confidence interval crosses zero.

Both confidence intervals cross zero. The trial establishes neither a clear benefit nor equivalence.

US, English-speaking pregnant/postpartum participants from racial or ethnic minoritized groups, with generally low baseline symptoms. 400 randomized; endpoint samples: anxiety 361, depression 362. Outcomes were self-reported. Rosie included incentives and human support; both groups could contact staff.

Sources and evidence

Sources

1. JAMA Network Open randomized trial, November 4, 2026

Supporting facts

• A randomized clinical trial of 400 pregnant or postpartum participants, published in JAMA Network Open on November 4, 2026, found no statistically significant difference in anxiety or depression at 12 months between access to Rosie and a monthly children's book control. [1]
• The US trial enrolled English-speaking participants aged at least 14 who were pregnant or parenting an infant younger than six months and self-identified as members of racial or ethnic minoritized groups; 200 participants were assigned to each study group. [1]
• The primary outcomes were self-reported anxiety symptoms measured with GAD-7 and depression symptoms measured with PHQ-9 at 12 months. [1]
• At 12 months, the adjusted mean difference for anxiety was 0.10 points (95% confidence interval, -0.77 to 0.96), and for depression it was -0.23 points (-1.05 to 0.59), comparing chatbot access with the book-club control. [1]
• Rosie was designed to provide maternal and infant health information, personalized guidance, reminders and educational support, with distress alerts reviewed by a clinical social worker who could contact participants and provide resources. [1]
• Chatbot users received small payments for asking questions and additional book incentives for the most active users; control participants received one children's board book per month for 12 months, and both groups could contact study staff. [1]
• Among participants with available baseline responses, the median GAD-7 score was 2 and median PHQ-9 score was 3, with 11.1% and 9.5% respectively meeting the study's moderate-to-severe symptom threshold. [1]

Method

Reported adjusted chatbot-minus-control differences and 95% confidence intervals. Interval geometry uses a shared -1.2 to +1.2 questionnaire-point domain, scaled linearly; no effect estimates are recalculated. Each option represents a different symptom questionnaire.

Scope

US, English-speaking pregnant/postpartum participants from racial or ethnic minoritized groups, with generally low baseline symptoms. 400 randomized; endpoint samples: anxiety 361, depression 362. Outcomes were self-reported. Rosie included incentives and human support; both groups could contact staff.

Infographic by CryptoSlate

Human support and low baseline symptoms in AI chatbot study

Participants received small payments for questions and book rewards for the most active users. The control group received one children's board book per month for a year, and both groups could communicate with study staff.

Those conditions limit how directly the findings translate to routine chatbot use.

Participants generally began with low symptom scores. Among those with available baseline responses, the median anxiety score was 2, and the median depression score was 3. About 11.1% and 9.5% of the participants, respectively, met the study's moderate-to-severe threshold.

Self-reported health outcomes are another limitation, and the authors urged caution about secondary and exploratory findings.

Rosie, delivered with incentives and human backup to this population, showed no statistically significant 12-month advantage on the two primary mental-health measures. Whether other AI interventions or different clinical populations would yield different results remains open.